BMAC injections represent an emerging regenerative medicine approach for treating shoulder pain. This autologous therapy utilizes concentrated bone marrow-derived stem cells and growth factors to potentially promote tissue healing and reduce inflammation.
The BMAC procedure involves harvesting bone marrow, typically from the posterior iliac crest, under local anesthesia. The aspirate undergoes centrifugation to concentrate stem cells and growth factors before ultrasound-guided injection into the affected shoulder region.
Initial recovery requires 24-48 hours of relative rest. Patients can gradually return to activities within 1-2 weeks. Full recovery potential is typically reached within 2-3 months, with continued improvement potentially occurring up to 6-12 months post-procedure.
Studies report minimal risks associated with BMAC injections. These include infection (less than 1% incidence), pain at harvest site, bruising, minor bleeding, temporary nerve irritation, and failed response to treatment.
Recent literature demonstrates varying degrees of success. Hernigou et al. (2014) reported 87% success rate in rotator cuff healing when BMAC was used as an adjunct to surgical repair. Kim et al. (2018) demonstrated significant pain reduction (mean VAS improvement of 3.4 points) and functional improvement (mean ASES score increase of 31.4 points) at 6 months post-injection. Centeno et al. (2020) showed 82.4% of patients reported improvement in pain and function at 12 months follow-up.
Several factors influence treatment outcomes, including patient age and overall health status, severity and chronicity of shoulder pathology, cell concentration and quality, technical precision of injection, and post-procedure rehabilitation protocol.
While promising, current literature suggests that optimal cell concentrations remain undefined. Standardization of protocols is needed, and long-term outcomes require further investigation. Cost-effectiveness studies are limited, and comparative effectiveness with other treatments needs additional research.
Most studies recommend initial 48-hour activity modification, followed by progressive return to normal activities over 1-2 weeks. A structured physical therapy program is advised, with sport-specific training after 6-8 weeks if applicable.
The best candidates typically include those who have failed conservative treatment, have chronic shoulder pain, rotator cuff pathology, early to moderate osteoarthritis, and good general health status.
Contraindications:
Treatment is contraindicated in cases of active infection, malignancy, severe anemia, platelet disorders, anticoagulation therapy, and systemic illness affecting bone marrow function.
Ongoing research focuses on optimizing cell concentrations, identifying ideal timing for intervention, developing standardized protocols, understanding mechanism of action, and determining cost-effectiveness.
The study is supported by research from Hernigou P, et al. (Arthroscopy, 2014), Kim SJ, et al. (Am J Sports Med, 2018), Centeno CJ, et al. (J Pain Res, 2020), Jo CH, et al. (Am J Sports Med, 2019), and Themistocleous GS, et al. (J Orthop, 2018).
Conclusion:
BMAC injections show promise as a treatment option for shoulder pain, with a favorable safety profile and encouraging early clinical outcomes. However, standardization of protocols and additional high-quality research are needed to establish optimal treatment parameters.
©2025 Dr Frank McCormick All Rights Reserved.
